Literature DB >> 4455570

A study of carbohydrate metabolism in postnecrotic cirrhosis liver.

R T Yeung, C C Wang.   

Abstract

Intravenous glucose tolerance, insulin tolerance, tolbutamide, and glucagon tests were carried out in 21 patients with postnecrotic cirrhosis. Based arbitrarily on the bromsulphthalein retention they were divided into group A, nine patients with less impaired liver function, and group B, 12 patients with greater impairment of liver function. Intravenous glucose and insulin tolerances were reduced in both groups. The hypoglycaemic effect of tolbutamide was similar in the controls and in both groups of cirrhotic patients but this was achieved at higher plasma insulin levels in group B indicating resistance of the liver to the effect of endogenous insulin. The blood glucose response to glucagon was markedly impaired in group B patients which is consistent with this hypothesis. In contrast to the insulin response to glucose and tolbutamide, the insulin response to glucagon was reduced in the cirrhotic patients. Fasting human growth hormone and free fatty acid levels were elevated in both groups but they were not considered to be important factors in the production of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4455570      PMCID: PMC1413049          DOI: 10.1136/gut.15.11.907

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

2.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.

Authors:  P J RANDLE; P B GARLAND; C N HALES; E A NEWSHOLME
Journal:  Lancet       Date:  1963-04-13       Impact factor: 79.321

3.  THE INTRAVENOUS GLUCOSE TOLERANCE TEST.

Authors:  E L Lozner; A W Winkler; F H Taylor; J P Peters
Journal:  J Clin Invest       Date:  1941-09       Impact factor: 14.808

4.  Plasma free fatty acid in liver disease.

Authors:  A MORTIAUX; A M DAWSON
Journal:  Gut       Date:  1961-12       Impact factor: 23.059

5.  Glucose tolerance and diabetes in chronic liver disease.

Authors:  C Megyesi; E Samols; V Marks
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

6.  Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects.

Authors:  J Olefsky; J W Farquhar; G Reaven
Journal:  Diabetes       Date:  1973-07       Impact factor: 9.461

7.  The behaviour of insulinaemia in patients ith liver cirrhosis after intravenous administration of glucose, tolbutamide and glucagon.

Authors:  T Kasperska; J Lawecki; H Rogala; A Czyzyk
Journal:  Diabetologia       Date:  1971-10       Impact factor: 10.122

8.  Glucose tolerance, free fatty acid, and serum insulin responses in patients with cirrhosis.

Authors:  D Berkowitz
Journal:  Am J Dig Dis       Date:  1969-10

9.  Decreased insulin production, elevated growth hormone levels, and glucose intolerance in liver disease.

Authors:  A Hernandez; E Zorrilla; H Gershberg
Journal:  J Lab Clin Med       Date:  1969-01

10.  [Intravenous injections of glucose, insulin and tolbutamide in healthy persons, diabetics, cirrhotics, and patients with insuloma (together with a contribution on the diagnostic value of the tolbutamide tests)].

Authors:  W CREUTZFELDT; K WILLE; H KAUP
Journal:  Dtsch Med Wochenschr       Date:  1962-10-26       Impact factor: 0.628

View more
  8 in total

1.  Effect of somatostatin (SRIF) on plasma glucose and insulin response to glucagon in liver cirrhosis.

Authors:  L Altomonte; A V Greco; G Ghirlanda; A G Rebuzzi; R Manna; A Bertoli
Journal:  Acta Diabetol Lat       Date:  1979 Apr-Jun

2.  C-peptide in non-alcoholic cirrhosis and hepatocellular carcinoma.

Authors:  K K Pun; P W Ho; R T Yeung
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

3.  Glycerol clearance in alcoholic liver disease.

Authors:  D G Johnston; K G Alberti; R Wright; P G Blain
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

4.  [Concentration of C-peptide and insulin in serum of patients with acute virus hepatitis (author's transl)].

Authors:  P Bottermann; T Zilker; R Ermler; K Paterek; B von Stransky
Journal:  Klin Wochenschr       Date:  1978-10-15

5.  Hyperglucagonaemia in cirrhosis. Relationship to hepatocellular damage.

Authors:  G Smith-Laing; H Orskov; M B Gore; S Sherlock
Journal:  Diabetologia       Date:  1980-08       Impact factor: 10.122

6.  Possible roles of insulin, glucagon, growth hormone and free fatty acids in the pathogenesis of insulin resistance of subjects with chronic liver diseases.

Authors:  E Bonora; S Orioli; C Coscelli; G Buzzelli; P Gentilini; U Butturini
Journal:  Acta Diabetol Lat       Date:  1984 Jul-Sep

7.  Oridonin prevents insulin resistance-mediated cognitive disorder through PTEN/Akt pathway and autophagy in minimal hepatic encephalopathy.

Authors:  Fangfang Wen; Weishan Zhuge; Jian Wang; Xiaoai Lu; Ruimin You; Leping Liu; Qichuan Zhuge; Saidan Ding
Journal:  J Cell Mol Med       Date:  2019-09-30       Impact factor: 5.310

Review 8.  Malnutrition in Patients with Liver Cirrhosis.

Authors:  Julia Traub; Lisa Reiss; Benard Aliwa; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-02-07       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.